Abnova Introduces CellTX™ Cell Therapy Reagents, Expands into Cell Therapy Market

Abnova Introduces CellTX™ Cell Therapy Reagents, Expands into Cell Therapy Market

Neihu, Taiwan (April 22, 2024)

Cell therapy has emerged as a leader in the medical industry, with its unique therapeutic mechanisms and immense potential to capture widespread attention globally. The FDA's approval of the world's first CAR-T product in 2017 marked a significant milestone, heralding a new era of rapid development in cell therapy technology, particularly in cancer treatment. Abnova has responded to market demands by launching the CellTX™ cell therapy reagent line, catering to the expanding field with three major categories of reagents.

1. Human and mouse CD3/CD28 ActiveBeads™:

The process of cell therapy requires the isolation and activation of specific cells from blood for in vitro expansion. Therefore, appropriate cell activation reagents are essential for developing cell therapy drugs. Abnova has invested in the development of T cell activation reagents, from the development of CD3 and CD28 monoclonal antibodies to antibody humanization and coupling with magnetic beads. Abnova has successfully developed Human CD3/CD28 ActiveBeads™. In response to the demand for mouse model testing during the development of cell therapy drugs, Abnova has simultaneously launched Mouse CD3/CD28 ActiveBeads™ to fully meet users' needs at various stages of development.

2. Humanized monoclonal antibodies related to cell therapy:

Humanized monoclonal antibodies play a crucial role in cancer research and the development of new drugs for autoimmune diseases. Leveraging years of antibody production experience, Abnova provides high-quality humanized monoclonal antibody catalog products for research related to cell therapy through antibody humanization engineering technology to meet market demands.

3. GMP-grade proteins for cell therapy manufacturing:

Cell therapy procedures require the isolation and in vitro expansion culture of specific cells, necessitating the use of various cytokines during the cultivation process. To meet the market demand for high-quality GMP-grade proteins for cell culture, Abnova has introduced GMP-grade products that comply with ISO 9001 certification and USP guidelines. These products are specifically designed for cell therapy cultivation to meet the growing demands of the expanding market.

Abnova is dedicated to advancing the field of cell therapy. We are committed to introducing high-quality cell therapy-related reagent products and continuously refining existing ones to meet the latest standards and technological requirements in the field. Our goal is to offer researchers more convenient and reliable tools, thereby fostering efficiency and facilitating progress in cell therapy development.

For Abnova CellTX™ cell therapy reagent catalog products, please refer to the following:

https://www.abnova.com/en-global/product?category=BA0000000000